Results for tag: "Synflorix"

Synflorix is a vaccine developed by GlaxoSmithKline (GSK) to protect against Streptococcus pneumoniae, a bacteria that can cause serious illnesses such as pneumonia, meningitis, and sepsis. It is a conjugate vaccine, meaning it contains a combination of bacterial polysaccharides and proteins. Synflorix is approved for use in infants and children up to five years of age, and is recommended for routine immunization in many countries. Synflorix is part of a larger market of pneumococcal vaccines, which are designed to protect against the various strains of Streptococcus pneumoniae. These vaccines are used to prevent serious illnesses, including pneumonia, meningitis, and sepsis. Other vaccines in this market include Prevnar 13, Synagis, and Pneumovax 23. Companies in the Synflorix market include GlaxoSmithKline, Pfizer, Merck, Sanofi, and AstraZeneca. These companies are involved in the research, development, and manufacture of pneumococcal vaccines. Show Less Read more